

# Paula Gonzalez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11098907/publications.pdf>

Version: 2024-02-01

65  
papers

5,345  
citations

117625

34  
h-index

106344

65  
g-index

65  
all docs

65  
docs citations

65  
times ranked

5051  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 743.	7.4	581
2	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. <i>PLoS ONE</i> , 2013, 8, e68329.	2.5	387
3	Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1444-1451.	6.3	274
4	Oral Human Papillomavirus in Healthy Individuals: A Systematic Review of the Literature. <i>Sexually Transmitted Diseases</i> , 2010, 37, 386-391.	1.7	249
5	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. <i>Lancet Oncology, The</i> , 2015, 16, 775-786.	10.7	247
6	Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease. <i>Journal of Infectious Diseases</i> , 2011, 203, 910-920.	4.0	245
7	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. <i>Cell</i> , 2017, 170, 1164-1174.e6.	28.9	221
8	Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. <i>Cancer Prevention Research</i> , 2013, 6, 1242-1250.	1.5	185
9	Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. <i>Lancet Oncology, The</i> , 2011, 12, 862-870.	10.7	168
10	Present status of human papillomavirus vaccine development and implementation. <i>Lancet Oncology, The</i> , 2015, 16, e206-e216.	10.7	165
11	Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1653-1662.	6.3	155
12	Cervicovaginal microbiome and natural history of HPV in a longitudinal study. <i>PLoS Pathogens</i> , 2020, 16, e1008376.	4.7	150
13	Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. <i>Vaccine</i> , 2008, 26, 4795-4808.	3.8	145
14	Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. <i>Cancer Discovery</i> , 2011, 1, 408-419.	9.4	143
15	Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 212.e1-212.e15.	1.3	108
16	Common Variants in Immune and DNA Repair Genes and Risk for Human Papillomavirus Persistence and Progression to Cervical Cancer. <i>Journal of Infectious Diseases</i> , 2009, 199, 20-30.	4.0	107
17	Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer. <i>PLoS ONE</i> , 2010, 5, e8667.	2.5	104
18	Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies. <i>Vaccine</i> , 2018, 36, 4774-4782.	3.8	103

#	ARTICLE	IF	CITATIONS
19	Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute, 2016, 108, djv302.	6.3	92
20	Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2020, 112, 1038-1046.	6.3	89
21	Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infectious Diseases, The, 2019, 19, 880-891.	9.1	85
22	Behavioral/Lifestyle and Immunologic Factors Associated with HPV Infection among Women Older Than 45 Years. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 3044-3054.	2.5	80
23	Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ: British Medical Journal, 2010, 340, c712-c712.	2.3	78
24	Comparison of Two PCR-Based Human Papillomavirus Genotyping Methods. Journal of Clinical Microbiology, 2008, 46, 3437-3445.	3.9	75
25	Comparison of the SPF <sub>10</sub>-LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica. Journal of Clinical Microbiology, 2007, 45, 1447-1454.	3.9	74
26	A Comparison of Cervical and Vaginal Human Papillomavirus. Sexually Transmitted Diseases, 2007, 34, 849-855.	1.7	73
27	Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2018, 110, 205-212.	6.3	71
28	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncology, The, 2020, 21, 1643-1652.	10.7	54
29	Prevalence of and Risk Factors for Anal Human Papillomavirus Infection Among Young Healthy Women in Costa Rica. Journal of Infectious Diseases, 2012, 206, 1103-1110.	4.0	51
30	Prevalence of and Risk Factors for Oral Human Papillomavirus Among Young Women in Costa Rica. Journal of Infectious Diseases, 2013, 208, 1643-1652.	4.0	47
31	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Journal of the National Cancer Institute, 2017, 109, djw300.	6.3	43
32	Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2020, 112, 1030-1037.	6.3	42
33	HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. PLoS ONE, 2013, 8, e53067.	2.5	39
34	Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer. PLoS ONE, 2012, 7, e33619.	2.5	37
35	Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses. Human Vaccines and Immunotherapeutics, 2013, 9, 1399-1406.	3.3	35
36	Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infectious Diseases, 2010, 10, 238.	2.9	34

#	ARTICLE	IF	CITATIONS
37	European Code against Cancer 4th Edition: Infections and Cancer. <i>Cancer Epidemiology</i> , 2015, 39, S120-S138.	1.9	34
38	Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. <i>International Journal of Cancer</i> , 2012, 131, 211-218.	5.1	29
39	Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2010, 37, 706-714.	1.7	27
40	Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment. <i>American Journal of Epidemiology</i> , 2013, 178, 752-760.	3.4	26
41	Evaluation of a Novel PCR-Based Assay for Detection and Identification of <i>Chlamydia trachomatis</i> Serovars in Cervical Specimens. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3986-3991.	3.9	25
42	Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia. <i>Cancer Prevention Research</i> , 2016, 9, 766-771.	1.5	25
43	Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naïve Women in HPV Vaccine Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1547-1554.	2.5	24
44	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju400-dju400.	6.3	24
45	Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays. <i>Frontiers in Oncology</i> , 2014, 3, 328.	2.8	24
46	Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. <i>BMC Infectious Diseases</i> , 2014, 14, 120.	2.9	22
47	molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. <i>Nature Communications</i> , 2022, 13, 233.	12.8	20
48	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 818-828.	6.3	19
49	Epidemiology of Genital <i>Chlamydia trachomatis</i> Infection Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2008, 35, 461-468.	1.7	18
50	Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure. <i>Sexually Transmitted Diseases</i> , 2011, 38, 976-982.	1.7	18
51	Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. <i>Journal of Infectious Diseases</i> , 2016, 213, 939-947.	4.0	18
52	Evaluation of the FTA Carrier Device for Human Papillomavirus Testing in Developing Countries. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3870-3876.	3.9	17
53	Reduced Prevalence of Vulvar HPV16/18 Infection Among Women Who Received the HPV16/18 Bivalent Vaccine: A Nested Analysis Within the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1890-1899.	4.0	17
54	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. <i>Vaccine</i> , 2015, 33, 2141-2151.	3.8	17

#	ARTICLE	IF	CITATIONS
55	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. <i>Journal of Infectious Diseases</i> , 2019, 220, 1609-1619.	4.0	17
56	Genetic Admixture and Population Substructure in Guanacaste Costa Rica. <i>PLoS ONE</i> , 2010, 5, e13336.	2.5	16
57	Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates. <i>American Journal of Epidemiology</i> , 2014, 180, 599-607.	3.4	14
58	Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. <i>Contemporary Clinical Trials</i> , 2018, 68, 35-44.	1.8	12
59	The Natural History of Oral Human Papillomavirus in Young Costa Rican Women. <i>Sexually Transmitted Diseases</i> , 2017, 44, 442-449.	1.7	10
60	Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. <i>Lancet Oncology</i> , The, 2022, 23, 940-949.	10.7	10
61	Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2965-2974.	3.3	7
62	Vaginal residence and pharmacokinetic preclinical study of topical vaginal mucoadhesive W/S emulsions containing ciprofloxacin. <i>International Journal of Pharmaceutics</i> , 2019, 554, 276-283.	5.2	7
63	Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 1576-1581.	4.0	7
64	Risk Factors for Non-HPV Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2021, 224, 503-516.	4.0	4
65	HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. <i>Npj Vaccines</i> , 2022, 7, 40.	6.0	1